XML 94 R41.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration Agreements - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail) - AstraZeneca Agreements [Member] - USD ($) $ in Millions |  |  | 9 Months Ended | 12 Months Ended | 36 Months Ended
--- | --- | --- | --- | --- | ---
Dec. 31, 2013 | Jul. 30, 2013 | Mar. 31, 2014 | Dec. 31, 2017 | Jun. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Royalty rate against projected net revenues |  |  |  | 40.00% |
Discount rate applied |  |  |  | 17.50% |
U.S./RoW [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Non-contingent performance period |  | 89 months |  |  |
Upfront, non-contingent and time-based payments received |  | $ 82.0 |  |  | $ 374.0
Remaining up-front, non-contingent and time-based payments |  | 292.0 |  |  |
Upfront, non-contingent and time-based payments with extended payment terms |  | 230.0 |  |  |
Contingent payment |  | 62.0 |  |  |
Total potential milestones |  | 875.0 |  |  |
Non-substantive milestones |  | 160.0 |  |  |
Commercial sales milestone |  | 325.0 |  |  |
U.S./RoW [Member] | Clinical and Development Milestone [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Substantive milestones |  | 65.0 |  |  |
U.S./RoW [Member] | Regulatory Milestone [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Substantive milestones |  | 325.0 |  |  |
China [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Upfront, non-contingent and time-based payments received | $ 16.2 |  |  |  |
Upfront, non-contingent and time-based payments with extended payment terms |  | 12.0 |  |  |
Contingent payment |  | 20.0 |  |  |
Total potential milestones |  | 348.5 |  |  |
Commercial sales milestone |  | 167.5 |  |  |
Proceeds from upfront payments |  | 28.2 |  |  |
Upfront payments received |  |  | $ 12.0 |  |
Commercial sales and other events milestone |  | 187.5 |  |  |
China [Member] | Clinical and Development Milestone [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Substantive milestones |  | 15.0 |  |  |
China [Member] | Regulatory Milestone [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Substantive milestones |  | $ 146.0 |  |  |

X
- Definition Commercial sales and other events milestone. + References No definition available. + Details
Name: | fgen_CommercialSalesAndOtherEventsMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payments related to commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_CommercialSalesMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of contingent payments provided for under the collaboration agreement. + References No definition available. + Details
Name: | fgen_ContingentPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The non-contingent performance period related to a deliverable under a collaboration agreement. + References No definition available. + Details
Name: | fgen_NonContingentPerformancePeriod
Namespace Prefix: | fgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the total amount of non-substantive milestones that could be earned upon the achievement of certain pre-determined events from the total potential amount of milestone payments under the collaborative agreement. + References No definition available. + Details
Name: | fgen_NonSubstantiveMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_PotentialMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of upfront payments included under the collaborative agreement as arrangement consideration with extended terms. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontPaymentsExtendedTerms
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of non-contingent upfront payments received under the collaborative agreement. + References No definition available. + Details
Name: | fgen_ReceiptFromUpfrontPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of remaining upfront and non-contingent and time based payments under the collaboration agreement. + References No definition available. + Details
Name: | fgen_RemainingUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Implied royalty rate used to find the net present value of future cash flows. + References No definition available. + Details
Name: | fgen_RoyaltyRateOnNetRevenue
Namespace Prefix: | fgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the total amount of substantive milestones that could be earned upon the achievement of certain pre-determined events from the total potential amount of milestone payments under the collaborative agreement. + References No definition available. + Details
Name: | fgen_SubstantiveMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsDiscountRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |